Archive for November 2023

Health inequities persist globally, affecting low-and-middle-income countries (LMICs) as well as ‘developed’ nations such as the US and EU. In response, numerous pharmaceutical companies have initiated health equity initiatives and investments. Organizationally, these endeavors often operate independently, housed in dedicated segments of the organization distinct from the commercial core business units. This shows the challenge…

At Akimbo, we define commercialization as successfully getting a product to patients in need worldwide. We argue that it’s the primary purpose of any life sciences company and should guide entrepreneurs from day one (if the goal is not to bring a new treatment to patients, then why start a biotech company in the first…

Identifying patients has always been a traditional challenge for companies focusing on rare diseases. Early pioneers in the rare disease space, such as Shire or Genzyme, had dedicated ‘patient finders’ who tirelessly navigated the healthcare professional (HCP) landscape, reaching out to general practitioners and actively seeking potential patients. However, in recent years, advancements in technology…